Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Osimertinib efficacy and T790M status via ddPCR in NSCLC
NCT05458726Phase 2Unknown
- Sponsor
- Peking Union Medical College
- Start
- Sep 2020
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of osimertinib in non-small cell lung cancer (NSCLC), sponsored by Peking Union Medical College. Status: unknown.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05458726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05458726.